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functioning MCID estimates for improvement and deterioration were (11, 2*) and 
those for communication deﬁ cit were (9, 7). The estimates with asterisks were less 
than the 0.2 SD threshold and were therefore excluded from our MCID ranges. Our 
MCID estimates therefore range from 5 to 14. CONCLUSIONS: These estimates can 
help clinicians to interpret the clinical relevance of changes in HRQOL over time and, 
in conjunction with other measures of efﬁ cacy, help to assess the value of a health-care 
intervention. The ﬁ ndings also indicate that more sensitive measures may be needed 
to detect certain changes. Furthermore, the estimates can be useful in determining 
sample sizes in the design of future clinical trials.
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OBJECTIVES: To clarify the details of psychosocial health status, the effects and 
related costs of psychosocial group intervention in post-breast cancer surgery patients. 
METHODS: Structured psychosocial group intervention (90 min/week × ﬁ ve sessions) 
was conducted for 66 patients aged 20–79 years who were receiving breast cancer 
treatment at three hospitals in Japan (intervention group). The intervention was 
conducted 2 weeks to 3 months after radical surgery. HRQOL and psychosocial 
function were investigated prospectively for outcome. The survey included 1) EORTC 
QLQ-C30 for HRQOL; and 2) POMS, MAC scale, and a characteristic self-efﬁ cacy 
scale for psychosocial function. It was conducted at registration, week 4 (group 
therapy conclusion), and month 6. Prior to the intervention study, a group that fulﬁ lled 
the same eligibility criteria but did not receive psychosocial group intervention was 
studied (n = 116; nonintervention group). The same outcomes were measured and 
compared using multivariate analysis adjusted for disease stage, chemotherapy, and 
hospital. Direct medical costs were obtained from receipt data, and information on 
travel expenses, direct nonmedical costs, and indirect costs (productivity costs) were 
collected simultaneously with the HRQOL survey. RESULTS: In HRQOL and psy-
chosocial function, an intervention effect was seen in fatalism (MAC_F) only. In a 
subgroup analysis by hospital, effects of cognitive function were seen in HRQOL 
(EORTC_CF), tension-anxiety (POMS_TA), helplessness/hopelessness (MAC_H), and 
fatalism (MAC_F). However, these effects were not seen at 6 months. Total medical 
costs including indirect costs during the 6 months were ¥840,000 for the intervention 
group and ¥750,000 for the nonintervention group. CONCLUSIONS: Structured 
psychosocial group intervention for post-breast cancer surgery patients had a uniform 
effect in improving HRQOL and psychosocial function. It is signiﬁ cant that a beneﬁ t 
was obtained in the early postoperative period when HRQOL is most easily damaged. 
Medical costs did not differ signiﬁ cantly between the groups.
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OBJECTIVES: For the last two decades, QL has been increasingly assessed in the 
EORTC. a detailed database review of all completed and ongoing EORTC QL studies 
has been undertaken. METHODS: A database of all EORTC QL clinical trial proto-
cols was established in 2000. This regularly updated database comprises all trials 
where QL has been included as an end point. It summarizes details of closed and 
ongoing trials, QL tools used, assessment timing, disease and treatment types, compli-
ance, and published outcomes. These were examined and reported. RESULTS: The 
database contains over 128 EORTC clinical trial protocols over a 15-year period 
between 1995 and 2010 which included a QL component. This is an average of eight 
new clinical trials with QL per year with only two having QL as a primary end point. 
The QLQ-C30 was the instrument of choice in 85% of trials. In the last decade, 15 
EORTC clinical groups have been recruiting patients. The majority of trials were 
conducted by the radiotherapy, brain and breast groups. Over 20,000 patients, mostly 
from Belgium, France, Germany, and the The Netherlands, have been entered into 
closed and ongoing multinational trials. Typically, EORTC trials are conducted across 
an average of 12 countries which include over 85 centers and often involve only a 
single trial. Several early EORTC trials experienced lower than ideal compliance. This 
presents a major challenge for the EORTC, but trials in the last 6 years have demon-
strated signiﬁ cantly improved compliance. Most QL studies were published as separate 
papers from the main clinical paper, and over 80% were published in high-impact 
factor journals (IF > 12). CONCLUSIONS: QL is now a major component of cancer 
clinical trials, an almost standard secondary end point. This suggests that researchers 
in the European context increasingly acknowledge the importance of patient-reported 
outcome assessments for evaluating cancer therapeutic modalities.
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OBJECTIVES: To compare hematological toxicity, costs, health-related quality of life 
(HR-QOL), and outcomes observed in real life in the Belgian non-Hodgkin lymphoma 
(NHL) population receiving 90Y-Zevalin, with model-predicted data at reimburse-
ment on the basis of a clinical trial in heavily pretreated NHL. METHODS: Twelve 
of the 13 centers trained for 90Y-Zevalin administration at the time of reimbursement 
approval participated. All consecutive patients receiving 90Y-Zevalin for Rituximab-
relapsed/refractory NHL were included in this 1-year, multicenter, prospective, obser-
vational study. QOL assessments, based on a generic (EQ-5D) and a disease-speciﬁ c 
(FACT-LYM) questionnaire, were performed at baseline (date of ﬁ rst administration 
Rituximab), day 8, month 1, 2, and 3 after baseline. Costing (c, 2008) was based on 
ofﬁ cial tariffs and observed resource use. RESULTS: Over the 2-year recruitment 
period, 30 patients were included. Only one1 patient received hematopoietic growth 
factor prophylaxis. Hematological toxicity occurred in 79% of patients, but was 
generally mild. Grade IV neutropenia was reported in 16% of patients (35% pre-
dicted), grade IV thrombocytopenia in 23% (9% predicted), and grade IV anemia was 
not reported (4% predicted). EQ-5D as well as FACT-LYM assessments suggested no 
signiﬁ cant changes in HR-Qol over the study period and no impact of hematological 
toxicity on HR-Qol. The average total cost from the health-care payer perspective, 
covering costs of drugs, drug administration setting, and prophylaxis, mounted to 
c16,886 (Standard error 79 c). Hematological toxicity added c1191 (Standard error: 
c528), constituting 7% of total costs (18,076 c). Observed costs were within 2% from 
predicted costs. Median time to progression (TTP) was 11.7 months (6.8 months 
predicted). CONCLUSIONS: This observational study conﬁ rmed the predicted toler-
ability proﬁ le, costs and outcomes associated with 90Y-zevalin in a real-life patient 
population. Furthermore, the patient numbers treated with 90Y-Zevalin in real life 
were lower than anticipated (maximum 100 predicted).
PCN131
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN CERVICAL CANCER: 
CLINICAL SIGNIFICANCE AND METHODOLOGICAL ISSUES
Siddiqui MK, Gupta J, Sehgal M
Heron Health Private Ltd., Chandigarh, India
OBJECTIVES: To assess the clinical use of HRQoL instruments in RCTs in cervical 
carcinoma and evaluate pertinent methodological issues. METHODS: RCTs investi-
gating HRQoL beneﬁ t of therapies in cervical carcinoma in adult females, published 
in English language were included. Cochrane Central Register of Controlled Trials, 
MEDLINE and EMBASE were searched from inception to 2010. Two reviewers 
independently assessed the trials for inclusion and performed extraction. RESULTS: 
Of the 96 RCTs identiﬁ ed, 13 RCTs met the inclusion criteria. Ten trials compared 
different chemotherapy regimens in ﬁ rst- to third-line treatment. The most commonly 
used QoL instrument was Functional Assessment of Cancer Therapy (FACT-G) (46% 
trials). Alternatively, cancer-speciﬁ c European Organization for Research and Treat-
ment of Cancer-Quality of Life Questionnaire-Core 30 (EORTC QLQ-30), SF-36, and 
Linear Analogue Scale Assessment (LASA 100 mm) were used either alone or in 
conjunction with the Brief pain Inventory (BPI). Only one trial reported HRQoL as a 
primary objective. HRQoL results were presented adequately in 61% trials which were 
analyzable. Statistically signiﬁ cant differences in HRQoL between treatment groups 
were studied in 69% studies, but the clinically meaningful difference was examined 
in only one study. Prognostic value of QoL was assessed in only two trials (15%). 
Most widely observed methodological issues included lack of priori hypothesis (92% 
studies) and lack of methods to deal with missing data (85%). Other issues included 
lack of details on domain, variability in time points of administration of a tool, and 
patient’s noncompliance, reported in ~60% studies. CONCLUSIONS: HRQoL is 
included as an outcome in the studies investigating therapies in cervical carcinoma but 
clinically meaningful interpretations of HRQoL results are rarely considered. The 
methodological shortcomings in the assessment and analysis of HRQoL outcomes 
should be examined further to derive clinically meaningful and correlating evidence.
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OBJECTIVES: Maintenance therapy can delay progression and prolong survival in 
metastatic non-small cell lung cancer (mNSCLC). The impact of treatments for 
mNSCLC on patient quality-of-life (QoL) is an important consideration, as treatment 
is noncurative and QoL in this population is already compromised. The SATURN 
study demonstrated that, compared with placebo, erlotinib maintenance therapy 
improved progression-free survival and overall survival by 41% and 23%, respec-
tively. The impact of erlotinib maintenance therapy on QoL was also evaluated as a 
secondary end point. METHODS: Patient QoL was assessed until disease progression 
or withdrawal using the Functional Assessment of Cancer Therapy-Lung (FACT-L) 
questionnaire. Disease progression was assessed radiographically at regular intervals, 
often diagnosed prior to symptomatic progression. Patient QoL was analyzed in terms 
